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Abstract
Urinary tract tuberculosis (UTTB) is an insidious disease with non-specific constitu-
tional symptoms that are often unrecognized and lead to delayed diagnosis. Advanced 
UTTB may cause loss of kidney function. In the majority of literature, UTTB is reviewed 
together with genital tuberculosis because often both sites are involved simultaneously; 
“Genitourinary tuberculosis” (GUTB) is the most common term used in the literature. 
However, the term may cause confusion because the clinical presentation and diagnosis 
approach is very different, and does not always occur simultaneously. UTTB is the term 
used here as we encountered tuberculosis involvement of urinary tract only. This book 
chapter is a comprehensive review of the epidemiology, pathophysiology, clinical pre-
sentation, diagnosis approach, and current treatment of this disease.
Keywords: tuberculosis, urinary tract infection, renal tuberculosis, extra-pulmonary 
tuberculosis, genitourinary tuberculosis
1. Introduction
Throughout history, tuberculosis (TB) has been identified as a respiratory disease, with prom-
inent symptoms as cough, fever, and wasting. Current clinical experience reveals that the 
lungs are involved in 80–90% of all TB patients not infected by human immunodeficiency 
virus (HIV). Extra-pulmonary forms are more common in people co-infected with HIV where 
genitourinary tuberculosis (GUTB) represents 27% [1].
GUTB is a term coined by Wildbolz in 1937 [2]; it is a worldwide disease, but shows a more 
destructive behavior in developing countries. The kidney is the most common site of GUTB 
[3], and it usually affects adults between the second and fourth decades of life and is reported 
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as being rare in children [4, 5]. Clinical renal TB is a chronic process that can start many years 
after the initial lung infection [6].
Renal involvement in TB can be part of a disseminated infection or a localized GUTB disease. 
With renal disease progression, extensive areas of papillary necrosis can cause formation of cav-
ities that destroy the renal parenchyma and can migrate into the collecting system. Advanced 
disease may cause obstructive uropathy, bladder defects, and loss of kidney function [7].
UTTB is underdiagnosed in most health care centers; the clinicians must have a high degree 
of suspicion for UTTB in patients presenting with non-specific symptoms, culture-negative, 
pyuria, and for whom imaging studies show some typical findings of UTTB. Acid fast bacilli 
(AFB) microscopy and Lowenstein Jensen (LJ) culture are the tests most used in health institu-
tions. AFB stain has a poor sensitivity and false positive can result from mycobacteria external 
genital colonization or by the presence of precipitates that resemble AFB. Although, LJ cul-
tures have a better sensitivity, it may require around 8 weeks to obtain growth and identifica-
tion [8]. In addition to other forms of extra-pulmonary tuberculosis, the amplification tests 
of deoxyribonucleic acid (DNA) have been used with good results, increasing the sensitivity, 
specificity and shortening the time to obtain the results. However, UTTB diagnostic requires 
a comprehensive approach and not just the use of a single test.
The initial treatment for TB in adults consists of the association of three or four different drugs, 
an intensive phase of 2 months of isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and 
ethambutol (EMB) followed by a continuation phase of 4 months of INH and RIF [9].
2. Epidemiology
The 2017 edition of the World Health Organization global TB report includes data available 
from 201 countries and territories that account for over 99% of the world’s population. In 2016, 
a total of 6.3 million new cases of TB were reported and extra-pulmonary TB represented 15% 
of the cases notified, ranging from 8% in the Western Pacific Region to 24% in the Eastern 
Mediterranean Region [10]. According to other registers, of the total TB cases reported, the 
most frequent types of extra-pulmonary TB were lymphatic (14.8–40.4%), pleural (7.8–19.8%), 
bones and/or joints (3.5–11%), and GUTB (1.7–6.5%) [11, 12]. Involvement of the kidneys is the 
most common form of tuberculosis of the genitourinary tract [13].
In UTTB, a history of pulmonary TB is present in 17.7–25.8% [14–16]. The time interval 
between the onset of primary pulmonary TB and development of GUTB has a mean interval 
of 3–10 years in more than 50% of patients [14, 15]. In frequency, renal involvement is the most 
common finding following by ureteric and bladder involvement [16]. Simultaneous involve-
ment of kidney, ureter, and bladder has been reported until a 25.8% [15, 16]. The incidence of 
active pulmonary TB concurrent with UTTB varied from 10 to 25.8%.
The proportion of immune-compromising conditions, such as malignancy, diabetes mellitus, 
chronic renal failure, and immunosuppressive drug use, are found as 46.7% [14]. The inci-
dence of TB has been estimated to be as much as 10-fold higher among renal failure patients 
than among the general population [17].
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3. Pathogenesis
Pulmonary infection is the primary focus in most cases of TB. After exposition, the bacilli 
remain stored in macrophages, where they slowly multiply, UTTB is the result of hematoge-
nous spread from the lungs. Once the bacilli reach the circulation system, it can be distributed 
to all parts of the body, especially those sites with adequate conditions for its multiplication 
and with local immune deficiencies [18, 19]. The lymphatic nodes, encephalus, and urinary 
tract are some of the most frequent sites involved [20, 21].
The kidneys, and possibly the prostate and seminal vesicles, are often the primary sites of 
GUTB. All other genital organs, including the epididymis and bladder, become involved by 
ascent or descent of Mtb from a source elsewhere in the genitourinary tract [22]. Mtb bacilli are 
shed into the urine; they spread into the urinary tract, involving the renal pelvis, ureters and 
bladder; the urinary tract mucosa may be ulcerated, thin and without contractility [4]. In most 
patients, acquired cellular immunity develops and there is inhibition of bacilli multiplication 
and containment of the disease by the formation of microscopic granulomas, leading caseous 
necrosis with local tissue destruction [18].
The infection occurs initially in the medullary region, where granulomatous lesions can occur. 
If, in the course of primary infection, cell-mediated immunity develops and the proliferation 
of organisms is limited by competitive macrophages, this results in the formation of granu-
lomas in which dormant bacilli can be maintained for long periods, leading caseous necrosis 
with local tissue destruction. When the bacilli are spilling down into the nephrons, they are 
trapped in the loop of Henle, establishing new foci of infection [18]. The multiple focus of 
microscopic necrosis lead macroscopic lesions that rapidly involve the renal papilla, causing 
fibrosis that can cause ureteral damage, with dilations intercalated with strictures, which con-
stitutes an important TB sign on the pyelogram [23].
Sites of the urinary tract where there are natural narrow strictures, such as the calyceal neck, 
the pelvi-ureteric junction, and the uretero-vesical junction are the sites that suffer strictures 
more frequently. Steroid therapy may be useful in the early stages of scarring and could 
reduce the risk of stenosis that can lead to urinary obstruction and irreversible kidney dam-
age [24]. A mass lesion may result from massive destruction and coalescence of granulomas, 
if they do not rupture into the adjoining calyx [25].
Hypercalcemia may occur, usually secondary to abnormal cortisol production by granulo-
matous tissue [26]. Although calcification is unusual in the early stages of the disease, nearly 
every end-stage tuberculosis kidney contains calcification. Hydronephrosis or hydrocalicosis 
may be the final stage, and may lead to a non-functioning, calcified kidney of any size; this 
process is called autonephrectomy [24].
4. Clinical presentation
UTTB has an insidious onset, no specific symptoms with atypical presentations [27], which lead 
to difficulty and delay the diagnosis in most health care centers [19, 20, 22, 28]. The majority 
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of patients present local symptoms such as frequent voiding, dysuria, pyuria, pain (back, 
flank or abdominal), and microscopic or macroscopic hematuria [4, 28–31]. Systemic symp-
toms of fever, night sweats, weight loss, and anorexia are less common [4, 29–31].
In a series of 115 cases with GUTB, the most common symptoms were reported to be flank pain, 
nicturia, frequent voiding and dysuria [32]. Figueiredo and Lucon [33] reported that storage 
symptoms (urinary frequency, urgency, urgency incontinence, nocturia), dysuria, and hema-
turia were the most common symptoms on admission, affecting 50.5, 37.9 and 35.6% of cases, 
respectively. Loin pain and fever were reported less frequent (34.4 and 21.9%, respectively).
Lower urinary symptoms occur whenever the disease spreads down to the ureters and blad-
der. Urinary symptoms suggestive of urinary tract infection, accompanied by pyuria and 
hematuria with no bacterial growth, suggest UTTB [7, 21, 34]. Pyuria and/or microscopic 
hematuria are present in more than 90% of cases. Heavy proteinuria and cellular casts are not 
generally seen and the plasma creatinine concentration is usually normal [21]. Advanced dis-
ease may cause obstructive uropathy, bladder defects, and loss of kidney function [7]. Table 1 
summarized the most frequent findings in large recent series of UTTB.
5. Case report
A 43-year-old woman was admitted to the hospital for fever, dysuria, and gross hematuria. She 
has a history of 2 years with progressive malaise, weight loss, and recurrent episodes of fever 
and dysuria that were treated with different antibiotics. Renal TB was diagnosed 1.5 years prior, 
receiving treatment during 6 months, improving her clinical conditions. However, despite anti-
TB therapy, she continued having recurrent episodes of fever and dysuria. She also reports 
having intermittent diarrhea for 1 year and fever with flank pain for 3 months. Her physical 
examination revealed a chronically ill woman with fever and oral candidosis. Cardiothoracic 
examination was normal with the exception of tachycardia. Abdominal examination revealed 
diffuse abdominal tenderness with flank pain, and lower limb edema was noted. Laboratory 
Ref Author, country Year* Patients 
no.
Fever Flank 
pain
Dysuria Hematuria Pyuria Renal 
failure
[13] Krishnamoorthy, India 2017 110 NR 27.3 25.5 11 NR 1.8
[14] Altiparmak, Turkey 2015 79 43 38 51 79.1 67.1 19
[15] Wagaskar, India 2016 31 29 45.1 32 19.4 NR 35.4
[16] Zhang, China 2016 120 22.5 49.1 60.8 25 NR NR
[35] García-Rodríguez, Spain 1994 81 34.6 56.8 67.9 4.9 19.8 1.2
[36] Gokce, Turkey 2002 174 19.5 43.5 43.1 39.6 NR NR
[37] Ye, China 2016 193 NR 49.2 61.1 63.2 19.2 NR
*Year of publication; NR, not reported.
Table 1. Clinical and laboratory features in UTTB (percent).
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studies revealed urinalysis with pyuria and hematuria. Two serologies for antibodies to HIV 
were positive. The smear of urine staining with Ziehl-Neelsen (ZN) demonstrated AFB, and 
mycobacteria cultures were performed. Her chest x-ray showed diffuse bilateral infiltrates con-
sistent with pulmonary tuberculosis (Figures 1 and 2). Renal ultrasonography (USG) showed 
both kidneys enlargement with marked dilation of renal pelvis and calyces. The findings on 
conventional urography were stricture sites of the ureters and renal pelvis with severe hydro-
nephrosis and ureter distortion (Figures 3 and 4). An abdominal computed tomography (CT) 
showed a large abscess in psoas muscle (Figures 5 and 6). Initial empiric antimicrobial therapy 
with ceftriaxone, ciprofloxacin, and anti-TB therapy were started. The abscess was aspirated by 
external incision with complete drainage. Cultures for pyogenic bacteria of the psoas abscess 
and urine were both negatives. A polymerase chain reaction (PCR) test for Mtb in urine was 
positive (Figure 7). The patient was discharged home after 8 days of hospital stay.
The patient was re-admitted to the hospital 6 days after home stay. She continues with fever 
and abdominal discomfort. On the hospital day seven, her condition started to deteriorate 
Figure 1. Chest radiograph showing diffuse micro-nodular infiltrates in both lung fields.
Figure 2. Magnified view of the left down lobe shows multiple micro-nodular infiltrates.
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Figure 4. Left renal pelvis with severe hydronephrosis and ureteral distortion.
Figure 5. Axial CT revealing involvement of left psoas muscle and para-aortic space with displacement of the left kidney.
Figure 3. Intravenous urography revealing a non-functioning left kidney. Important deformity and dilatation of the 
collecting system, with ureteral tortuosity.
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and she died despite aggressive support Mycobacterial culture media subsequently yielded 
Mtb susceptible to all primary anti-TB drugs.
6. Diagnostic approach
The diagnosis of UTTB is a challenge owing to the insidious onset of UTTB with few and non-
specific symptoms, technical difficulties to isolate Mtb and the long time required to confirm 
the diagnosis by classical conventional methods of cultivation, lack of awareness of physi-
cians, and poor care-seeking behavior [33, 38].
The diagnosis of UTTB is usually performed in patients with clinical manifestations or abnor-
mal urinalysis with findings that suggest UTTB. Urinalysis may vary from mild changes, such 
Figure 6. Axial CT revealing left psoas muscle abscess of 7 × 5 cm (1) and para-aortic lymph nodes (2).
Figure 7. A representative image of PCR showing a DNA product of 200 base pairs for the first amplification. A positive 
control on the first line with a positive test on line 5.
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as proteinuria and leukocyturia, to extreme pyuria, sometimes accompanied by hematuria. 
There are some characteristics in urine examination that suggest a diagnosis of renal TB, such 
as acid pH, leukocyturia and/or hematuria, associated with negative urine culture for the 
usual bacteria that causes urinary tract infection [23].
There are several diagnostic methods for this entity. Here, we review the most common pro-
cedures used: (1) ZN staining and cultures isolation for Mtb in urine, (2) PCR for Mtb, (3) 
imaging studies, and (4) histopathological evidence for TB [14].
6.1. ZN stain and cultures for Mtb in urine
AFB can be seen in centrifuged urine by ZN staining, but it has low sensitivity when only 
few bacilli are seen. Also, it can be the result of urine contamination by non-pathogenic 
Mycobacterium spp., which can lead to false positive results [21].
Culture and identification provide a specific diagnosis, but might not be available for 2–3 weeks 
or longer. Multiple samplings should be obtained to increase test sensitivity; at least three dif-
ferent samples on LJ solid culture medium are recommended to maximize the likelihood of a 
positive result. Urine cultures are regularly negative, unless there is severe bladder dysfunc-
tion. Among patients with active renal TB, 30–40% of single urine specimens will be positive 
by Mycobacterium culture [39, 40]. BACTEC showed to be a better culture method compared 
to LJ, with a sensitivity of 37.5% and a specificity of 100% and the mean detection time for Mtb 
was 24.0 days by L-J medium culture versus only 12.8 days by BACTEC [41, 42].
6.2. Polymerase chain reaction for Mtb
The PCR assay has been extensively used as diagnosis in many forms of extra-pulmonary TB 
[43, 44], including some UTTB case reports [45, 46].
As a rapid and sensitive diagnostic method, PCR for Mtb identification in the urine has become 
the ideal diagnostic tool in recent years. It allows to make a diagnosis even when there are few 
bacilli and AFB detection is not possible. The sensitivity of AFB detection by ZN technique is 
between 42.1 and 52.1%. The sensitivities of culture methods vary from 10 to 90% while PCR 
in detecting Mtb in urine have a sensitivity that varies from 25 to 93% and a high specificity 
of 95–100% [38, 47–50]. In a prospective study in 42 patients where PCR was used, it showed 
a better sensitivity than the urine culture (80.9% against 30.9%); the author concludes that the 
PCR is far superior diagnosis technique for UTTB with high sensitivity and specificity, avoid-
ing the retard of the start of therapy [51].
In the recent years, there has been important effort to increase the PCR for Mtb detection capac-
ity, to avoid false positives by contamination and to determine his utility in different clinical 
samples [52–54]. In comparison with the traditional PCR of a single amplification, nested PCR 
consists of performing a second DNA step in order to increase sensitivity. According to the 
amount of DNA that is obtained, the nested PCR can enhance the sensitivity in approximately 
1000 times than the PCR of a single amplification [55–57].
In a study with 417 clinical samples (including 28 of urine), the nested PCR for Mtb had a sensi-
tivity of 97% and a specificity of 92% including positive results in some patients with negative 
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culture. The authors concluded that the nested PCR is superior in sensitivity and rapidity 
than the traditional methods [57]. Nested PCR display a better sensitivity than the first DNA 
amplification, increasing the detection limit from 10 pg to 10 fg that is equivalent to two cells 
in the second amplification. The great amount of DNA in the second step of the nested PCR 
make easy the detection; it has been reported that during the first amplification, many posi-
tive samples gave a relatively weak or doubtful band. In contrast, in the second amplification 
a a strong positive band was observed [57].
6.3. Imaging studies
Although it is usually stated that imaging studies are only suggestive of the disease and 
should not be used for the confirmation or exclusion of UTTB [58], the intravenous urography 
(IVU) has been the image study more used for this entity; anatomical alterations of the collect-
ing system can be seen with some facility. USG, CT, and magnetic resonance imaging (MRI) 
are less invasive methods that are better for detecting lesions in organs and tissues, including 
tumors, abscesses and calcifications; these can be done in addition to the IVU [59].
6.3.1. Plain radiograph
UTTB commonly results from hematogenous spread from a pulmonary focus; nevertheless, 
only 36.5% of patients with UTTB have a previous diagnosis of TB or abnormal imaging stud-
ies [5]. Chest radiograph will be normal in half the patients [60]. But, only 10% of chest radio-
graph will show signs of active TB [60, 61].
The greatest use of simple radiography is to demonstrate calcifications that can represent 
infections in extra-pulmonary sites, such as lymph nodes, liver, and spleen. Also, simple radi-
ography can identify psoas abscesses and abnormalities of the spine [4, 62]. In UTTB, calcified 
lesions are mainly located in renal and upper collector system in 24–44% of cases [61], and this 
finding may be the first sign that TB is present [60]. Fine calcifications that were previously 
unidentifiable are now much better seen with CT [59].
Calcifications can be small calcifications, multiple, or large single calcifications [63]. These are 
usually amorphous calcifications located in the renal parenchyma or can take the form of the 
collecting system where they lodge and tend to be granular or curvilinear [22, 64]. The calcified 
caseous tissue in the kidneys may look like ground glass, known as “putty kidney”. Premkumar 
et al. [65] termed “putty kidney” if the uniform calcification was greater than 1 cm in diameter.
Apperson et al. [66] emphasized the difficulty of differentiating calcifications from calculi in renal 
TB. In their cases of renal TB, 9.3% had discrete calculi and 8.7% had parenchymal calcification.
6.3.2. Intravenous urography
IVU has been considered the radiographic procedure of choice due to its ability to show the 
collector system like no other, and less frequently modern techniques such as computerized 
axial tomography and magnetic resonance are also used [67]. Early findings are best dem-
onstrated on contrast-enhanced tomography which is replacing IVU as the investigation of 
choice in that situation. In a retrospective study conducted in Spain, IVU guided the diagnosis 
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in 28/32 cases (87.5%), with calculus lesions, bladder alterations, hydronephrosis, calcifica-
tions and ureteral stenosis as the most common alterations [68]. However, 10–15% of patients 
with active UTTB may have normal urographic findings [69].
Early alterations of UTTB are located mainly in calyces, UVI can show minimal calyceal dila-
tion and loss of calyceal sharpness [61]. Although the calyceal damage is an early sign of 
UTTB, papillary necrosis could be the first sign observed [59]. As the disease progresses, the 
irregularity of the calices increases and may have a moth-eaten appearance [4, 25]. Other 
advanced manifestations include extensive cavitation, fibrotic strictures, cortical scars, mass 
lesions, calcification, autonephrectomy, perinephric abscess, and fistula formation [60].
6.3.3. Ultrasonography
USG is a readily available technique for demonstrating the various morphologic abnormalities 
found in renal TB [18, 70] and is a convenient method for guiding needles for fine-needle aspira-
tion cytology (FNAC) [71, 72]. USG has convenient, low-priced, and non-invasive advantages; a 
disadvantage is that a mass may be missed if its echogenicity is similar to the renal parenchyma.
Traditionally, USG has been considered of less value than IVU or CT in UTTB cases [6, 73]. 
USG has limitations in detecting subtle urothelial lesions, as well as isoechoic parenchymal 
masses and is not useful for evaluating renal function [65, 69]. However, a well-detailed study 
can provide valuable information. In a large retrospective study, the coincidence rate of USG 
in the diagnosis of renal TB was 58.9% [74]. As the disease progresses, both an infiltrative pat-
tern affecting the tissues and a pattern that affects the collecting system can be observed. In the 
first case, papillary destruction, calcifications, infected debris, hypoechoic masses or abscesses 
can be observed, in the second case dilated calyces, small renal pelvis, hydronephrosis, distor-
tion of renal morphology, deformity of the ureters, and bladder atrophy can be found [75, 76].
On the USG, renal abscess is presented as a semi-solid echogenicity and a thick ill-defined 
wall that can extend and drain, causing perinephric abscess that later may cause a cutaneous 
fistula [21, 68].
6.3.4. Computed tomography
CT is useful both in the diagnosis of renal TB and in assessing its severity in terms of loss of 
renal function and involvement of other organs in the abdomen [77]. It directly visualizes the 
renal parenchyma, irrespective of renal function and, in addition, assesses extrarenal spread 
of the disease. The CT nephrogram is not as dependent on renal function as is an IVU. CT is 
also useful in identifying renal scars, mass lesions, and urothelial thickening, all of which are 
common findings in renal TB [78].
In general, CT shows more details of pathologic anatomy due to the availability of axial 
images for review and is superior to retrograde pyelography, IVU, and USG in detecting 
multiple small urothelial lesions [79]. It can detect calcification with greater accuracy, preci-
sion, and sensitivity [61] and is the most sensitive modality for identifying renal calcifications, 
which occur in over 50% of cases of GUTB [80]. CT is also the best modality for demonstrat-
ing the extent, nature, and distribution of calcification within the abnormal kidney [65]. The 
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implementation of CT urography with multidetector technology improves the assessment of 
renal and urinary tract lesions using reformatted images [17].
The disadvantages of CT include its inability to identify very early changes of TB such as small 
parenchymal and subtle papillary necrosis. UTTB is characterized by a vast presentation that 
is of great diagnostic value [19, 62, 81]. In early disease, CT can detect obstruction of a single 
major or a group of minor calyces as well as abnormalities in the collector system (dilatation 
or contraction of the renal pelvis). In advance disease, the kidneys are small with replacement 
of parenchyma by one or more low density areas. Parenchyma or calyces calcifications are 
seen at 37% [81]. Newer scanners, if used meticulously, may be able to identify small granu-
lomas. The needs to use contrast and radiation issues, especially in young patients, are other 
limitations of CT studies that are not encountered on USG [78].
6.3.5. Magnetic resonance imaging
MRI provides morphological details of the kidneys as well as excellent delineation of the ure-
ters [67]. It allows characterization of various renal masses and can provide valuable informa-
tion contributing to their clinical management [82, 83]. It is particularly useful in pediatric or 
pregnant patients or when ionizing radiation and iodinated contrast cannot be administered. 
Non-contrast MRI is especially useful in patients with renal failure [67].
Magnetic resonance urography (MRU) comprises an evolving group of techniques with the 
potential for optimal non-invasive evaluation of urinary tract abnormalities. Both static-fluid 
(non-contrast, heavily T2W sequences) and excretory MRU (performed during the excretory 
phase of enhancement after intravenous gadolinium) can be combined with conventional 
MRI for comprehensive evaluation of the urinary tract. MRU demonstrates the ureters in 
their entirety and is useful for confirming the presence of stenosis [84]. It is most successful in 
patients with moderately to severely dilated or obstructed collecting systems and in impaired 
renal function situations [84, 85]. MRU performed with a distended urinary bladder allows 
better visualization of the upper urinary tract [86]. Time-resolved dynamic contrast-enhanced 
MRU has been used in the evaluation of ureteral peristalsis in GUTB [87]. In view of the pos-
sibility of nephrogenic systemic, fibrosis/nephrogenic, fibrosing dermopathy, caution should 
be exercised while administering gadolinium in patients with compromised renal function 
[88]. There are very few articles available in the literature on MRU in renal TB and hence the 
appearance of the same is still not widely known.
6.3.6. Fine-needle aspiration cytology
Sonographically guided FNAC is useful as a means of diagnosing of renal and genital (epidid-
ymitis and epididymo-orchitis) abscess or masses, and is of value in defining the granuloma-
tous nature of sonographically visible lesions [72]. Histologic findings of renal or genital TB 
are similar to those of TB elsewhere in the body (granuloma formation, non-specific inflam-
matory infiltrate). The granulomas appear with central Langerhans cells surrounded by lym-
phocytes, fibrocytes, and epithelioid cells, which later progress to central caseous formation 
and varying degrees of fibrosis and calcification. AFB may be detected on FNAC smears in up 
to 60% of these patients [72, 89].
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The advantages of USG-guided FNAC are that it is rapid, inexpensive, versatile, does not 
require the injection of any contrast medium, and can be easily repeated when necessary [90]. 
USG-guided FNAC is now widely accepted as a safe diagnostic procedure in various neoplas-
tic and non-neoplastic disorders [91, 92].
7. Treatment
A multidisciplinary approach with infectious disease and urology teams is crucial to provide 
optimal patient care; tuberculosis medications remain the cornerstone of treatment and surgi-
cal management is reserved for specific indications. There is lack of standardized treatment 
regimen for UTTB, it is accepted that pulmonary and extra-pulmonary TB should be treated 
with the same regimens.
The objectives of TB therapy are (1) to rapidly reduce the number of actively growing bacilli 
in the patient, thereby decreasing severity of the disease and preventing death (2) to eradi-
cate populations of persisting bacilli in order to achieve durable cure (prevent relapse) after 
completion of therapy; and (3) to prevent acquisition of drug resistance during therapy.
7.1. Medical treatment
Clinical judgment and the index of suspicion for TB are critical in making a decision to initiate 
treatment [9, 14]. Therapy should be initiated promptly even before the results of AFB smear 
microscopy, molecular tests, and mycobacterial culture are known. It is particularly impor-
tant in cases admitted with episodes of cystitis concomitant with sterile pyuria and progres-
sive renal parenchymal damage not related to other clinical diseases [14]. If the diagnosis has 
been made while renal function still remains, it may be possible to arrest the fall in glomerular 
filtration rate or even produce improvement, using a combination of anti-TB treatment and 
corticosteroids [21].
Fibrotic alterations can be decreased by use of corticosteroids in association with anti-TB drugs. 
However, despite these strategies, patients with advanced disease or those with a delayed diag-
nosis might require surgery [93]. The use of corticosteroids in addition to stenting for ureteral 
obstruction is discussed in the literature, and its efficacy in this setting remains unclear [94].
Regarding the duration of the UTTB treatment, the expert recommendation is that a standard 
daily 6-month regimen is adequate [12, 29, 31, 95, 96]. In countries where new cases of tuber-
culosis are resistant to organisms (resistant to isoniazid ≥4%), it is recommended to use four 
drugs in the intensive phase: INH, RIF, PZA, and EMB [97–101].
Two regimens can be used. The first-line regimen, which is used for 6 months, is with INH, 
RIF, PZA, and EMB administered daily or 5 days per week for 2 or 3 months, followed by INH 
and RIF daily or 5 days per week for 3 or 4 months [93]. The second-line regimen, which is 
recommended for TB caused by drug-susceptible organisms when directly observed therapy 
(DOT) is difficult to achieve, it consist of INH, RIF, PZA, and EMB daily or 5 days per week for 
2 or 3 months, followed by INH and RIF 3 times a week, for 3 or 4 months (Tables 2 and 3) [9]. 
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Pyridoxine (vitamin B6) is given with INH to all persons at risk of neuropathy (e.g., pregnant 
women; breastfeeding infants; persons infected with HIV; patients with diabetes, alcoholism, 
malnutrition, or chronic renal failure; or those who are of advanced age) [102, 103]. Although 
there is no studies that compare 5 with 7 daily doses, experts believe that the treatment of 
intensive phase with 5-days-a-week is as effective as 7-days-a-week [9].
Some authors propose that prolonged anti-TB treatment effectively sterilizes caseous and cal-
cified masses of the involved kidney, whereas others believe that the sequestered caseous 
material should be removed to shorten the duration of medical therapy and to prevent late 
TB reactivation [28, 104].
Adequately controlled, randomized studies specific to UTTB comparing different treatment 
regimens have not been performed. Such studies would establish if short-course therapies are 
adequate to ensure eradication of UTTB, including patients with prostatic infection. There is 
little information about the vigilance and follow-up of patients with UTTB that may include at 
least monthly function renal tests, urine ZN smear, and Mtb cultures. ADN amplification tests 
for Mtb and imaging studies should be used on clinical judgment and probably performed 
at the end of both intensive and continues phases. Response to treatment may be difficult 
to assess and should be based on clinical, radiologic, and eradication of Mtb on subsequent 
cultures [94].
Intensive phase Continuation phase
Drugs Interval and dose (minimum 
duration)
Drugs Interval and dose (minimum 
duration)
Range of total doses
INH 7 d/wk for 56 doses
(8 wk), or
5 d/wk for 40 doses
(8 wk)
INH 7 d/wk for 126
doses (18 wk), or
5 d/wk for 90
doses (18 wk)
182–130
RIF RIF
PZA
EMB
DOT, directly observed therapy; EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin.
Table 2. Recommended drug regimen for tuberculosis caused by drug-susceptible organisms.
Intensive phase Continuation phase
Drugs Interval and dose (minimum 
duration)
Drugs Interval and dose (minimum 
duration)
Range of total doses
INH 7 d/wk for 56 doses
(8 wk), or
5 d/wk for 40 doses
(8 wk)
INH 3 times weekly for 54 doses (18 wk) 110–94
RIF RIF
PZA
EMB
DOT, directly observed therapy; EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin.
Table 3. Recommended drug regimen for tuberculosis caused by drug-susceptible organisms when DOT is difficult to 
achieve.
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To maximize completion of therapy, management strategies should utilize a broad range of 
approaches. Among these, DOT is the practice of observing the patient swallow their anti-TB 
drugs and has been widely used as the standard of practice in many TB programs. DOT can 
be advantageous for early recognition of adverse drug reactions and treatment irregularities. 
DOT remains the standard of practice in the majority of TB programs in the United States 
[105, 106] and Europe [107].
Gastrointestinal and skin disorders adverse reactions are common; the frequency can reach 
up to 30% especially early in therapy. Less frequent adverse events are muscle-joints disor-
ders, fever, headache, hepatic problems, and even death [108, 109]. Four-drug fixed-doses 
therapy may reduce the incidence of gastrointestinal adverse effects and the use of antacids 
or proton pump inhibitors for reducing gastrointestinal can contribute to better tolerance with 
minor impact on drugs absorption [110]. INH, RIF, and PZA can cause drug-induced liver 
injury that is the most frequent serious adverse event [111]. It is necessary to promote some 
strategies that improve the quality of patient care and to control TB safely, treating preexisting 
diseases or dysfunctions, such as diabetes and alcoholism. These strategies may improve the 
patient adherence to treatment and therapeutic outcome.
7.2. Invasive procedures
Invasive procedures or surgery are indicated in certain situations: hydronephrosis drainage 
(ureter dilation or percutaneous nephrostomy), abscesses and collection drainage, definitive 
treatment of renal TB (partial nephrectomy), superior urinary tract reconstruction, bladder 
dilation, ureter reconstruction and others [112]. In a study of 4298 patients with GUTB, 2364 
(37%) underwent surgery: remove or preserve an organ and reconstruction surgery were the 
most frequent interventions. Other surgical modalities included ureteral neoimplantation 
using intestinal transplants (ileocystoplasty, sigmoidocystoplasty, and cecocystoplasty) [113].
Other surgical intervention can be double-J stenting use and percutaneous nephrostomy for 
hydronephrosis cases, drainage of abscesses, partial or polar nephrectomy, reconstruction of 
the upper urinary tract, and bladder augmentation with ileum replacement [114].
The standard treatment for a unilateral nonfunctional kidney secondary to renal TB is a nephrec-
tomy combined with anti-TB therapy [16]. The patients that end up in nephrectomy have an 
advanced stage [13, 37]. Nephrectomy is recommended only in cases of secondary sepsis, bleed-
ing, pain, uncontrollable hypertension, and continued positive urinary cultures for Mtb [38].
Radical or reconstructive surgical interventions are recommended be carried out in the first 
2 months of intensive GUTB therapy [115].
7.3. Treatment of special situations
7.3.1. Patients with HIV infection
HIV and TB create a deadly synergy, speeding the progression of both diseases. HIV enhances 
the reactivation and progression of latent TB to overt TB disease. The treatment represents a 
challenge were the most significant concern is to avoid drug-drug interactions and the control 
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of adverse events. Whenever possible, the use of combination formulations, both antitubercu-
lous and ARV drugs, is recommended in order to simplify the treatment.
The recommendation for HIV-infected patients receiving ARV and initial TB disease with sus-
ceptible Mtb is a short course of 6 months of therapy. During the first 2 months of daily regi-
men (initial phase), patients should be treated with INH, RIF, PZA, and EMB. This is followed 
by a continuation phase of 4 months of INH plus RIF thrice-weekly regimen. HIV-infected 
patients that still do not receive ARV; the recommendation is to extend the continuation phase 
with INH and RIF for additional 3 months (i.e., a continuation phase of 7 months in duration, 
corresponding to a total of 9 months of therapy) [9].
Once a week, TB continuation phase regimen can be safe and effective treating pulmonary TB 
in HIV-negative patients without cavitation on chest radiography [116]. However, relapses 
and rifamycin monoresistant tuberculosis occurs among HIV infected patients treated with 
a once-weekly isoniazid/rifapentine during continuation phase regimen [117]. A study with 
169 HIV-infected patients and pulmonary TB, nine (5.3%) had failure or relapse, eight of these 
nine isolates were detected with acquired rifamycin resistance, low CD4 lymphocyte counts 
and the use of twice-weekly therapy during intensive phase were the most important factors 
associated [118]. Lower plasma rifabutin and INH concentrations are associated with acquir-
ing rifamycin resistance [119].
HIV/TB co-infected patients treated during continuation phases with thrice-weekly anti-TB 
regimen showed a higher risk of relapse and death as well as emergence of rifamycin resistance 
compared with HIV-uninfected patients. ARV therapy reduces but does not eliminate the risk of 
these complications [120]. A prompt diagnosis of HIV, earlier ARV initiation, and avoiding inter-
mittent TB treatment regimens could prevent relapses and drug resistance emergence. Rifabutin 
can be substituted for RIF to decrease drug interactions with drugs used in the treatment of HIV 
infection (protease inhibitors and transcriptase reverse non-nucleoside inhibitors) [9].
Immune reconstitution inflammatory syndrome (IRIS) is a paradoxical clinical worsening of 
a known or new condition occurring shortly after initiating ARV therapy, mainly in patients 
with low CD4+ cell counts [121]. Mtb is among the most frequently reported pathogen associ-
ated with IRIS; signs may include high fever, lymphadenopathy, worsening of respiratory 
symptoms, new pulmonary infiltrates, and pleural effusions. Extra-pulmonary presentations 
are also possible expanding to central nervous system, intra-abdominal abscesses, osteomy-
elitis, and others [122]. For more severe cases of IRIS, treatment with corticosteroids is effec-
tive. In a placebo-controlled trial of prednisone for patients with moderate IRIS, prednisone 
1.25 mg/kg/day significantly reduced the need for hospitalization or surgical procedures [123].
7.3.2. Renal failure
Renal TB can result in acute or chronic renal failure with an incidence of 24%. If renal TB 
progresses to chronic kidney disease (CKD), it has effects in the immune system too. The 
alterations on systemic immunity included persistent systemic inflammation and acquired 
immunosuppression state [124]. The mechanisms associated with end-stage renal disease 
include obliterative endarteritis, renal amyloidosis, and obstructive uropathy [7, 93].
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The patients with CKD by other etiology are at increased risk of TB than those with nor-
mal renal function. Drug-induced hepatitis and all-cause mortality are more common among 
TB patients with CKD [125]. One of principal factors to consider in TB treatment with CKD 
included drug pharmacokinetics, drugs removed by hemodialysis that should be dosed after 
dialysis [126]. INH, RIF, and EMB are not significantly dialyzed. However, PZA is removed 
by hemodialysis and should be administered after hemodialysis [127]. Other factors included 
co-existent illnesses, dosage adjustment, drug interactions, and drug accumulate predispos-
ing to toxicities. Initial regimen with standard doses and no more than three times weekly for 
PZA, EMB, and aminoglycosides is recommended [128].
The fluoroquinolones used for TB treatment are levofloxacin, moxifloxacin, and gatifloxa-
cin. According to degree of renal impairment, levofloxacin dosage adjustment is required. 
Nevertheless, neither hemodialysis nor continuous ambulatory peritoneal dialysis removed 
levofloxacin [129]. Moxifloxacin may be administered at the normal dosage even with severe 
renal failure [130].
7.3.3. Advanced age
Age over 60 years is significantly associated with serious adverse events related to INH, 
PZA, and RIF, with greater frequency of hepatitis episodes and gastrointestinal intolerance 
[131, 132]. However, the risk of hepatotoxicity in advanced age might not increase after 
12 weeks with standard treatment containing INH and RIF [133]. The severity of INH-
induced hepatitis has been associated with higher mortality in this patient population [131]. 
Dose adjustments or alternative regiments should be considered to avoid stopping the treat-
ment, increasing the probability of failure and mortality [9, 134]. The duration of TB treatment 
depends of initial regimen during the intensive phase [9].
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